Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Sold by XTX Topco Ltd

XTX Topco Ltd decreased its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 54.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,198 shares of the company’s stock after selling 49,724 shares during the period. XTX Topco Ltd owned about 0.07% of Black Diamond Therapeutics worth $65,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in Black Diamond Therapeutics by 41.8% during the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock worth $43,000 after buying an additional 5,932 shares during the last quarter. Barclays PLC lifted its position in Black Diamond Therapeutics by 10.7% in the fourth quarter. Barclays PLC now owns 86,545 shares of the company’s stock valued at $186,000 after acquiring an additional 8,394 shares during the last quarter. Hsbc Holdings PLC lifted its position in Black Diamond Therapeutics by 99.0% in the fourth quarter. Hsbc Holdings PLC now owns 27,159 shares of the company’s stock valued at $59,000 after acquiring an additional 13,511 shares during the last quarter. Geode Capital Management LLC lifted its position in Black Diamond Therapeutics by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 959,316 shares of the company’s stock valued at $2,053,000 after acquiring an additional 14,439 shares during the last quarter. Finally, DAFNA Capital Management LLC lifted its position in Black Diamond Therapeutics by 12.0% in the fourth quarter. DAFNA Capital Management LLC now owns 140,000 shares of the company’s stock valued at $300,000 after acquiring an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 95.47% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Raymond James Financial raised shares of Black Diamond Therapeutics to an “outperform” rating and set a $11.00 target price for the company in a report on Tuesday, July 1st. Zacks Research raised shares of Black Diamond Therapeutics to a “strong-buy” rating in a report on Monday, August 11th. Finally, HC Wainwright reduced their target price on shares of Black Diamond Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a report on Monday, August 11th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $12.40.

Black Diamond Therapeutics Stock Performance

Shares of NASDAQ:BDTX opened at $2.76 on Friday. The stock has a market capitalization of $157.15 million, a price-to-earnings ratio of 12.00 and a beta of 2.87. Black Diamond Therapeutics, Inc. has a one year low of $1.20 and a one year high of $6.75. The company has a 50-day simple moving average of $2.65 and a 200-day simple moving average of $2.15.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06. As a group, research analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.